Amneal Pharmaceuticals, Inc.: directors' dealings · United States · SEC (Form 4)

About Amneal Pharmaceuticals, Inc.

Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) is a U.S.-listed biopharmaceutical company traded on the NASDAQ market in the United States, with headquarters in Bridgewater, New Jersey, United States. The company was founded in 2002 by brothers Chirag and Chintu Patel around a clear mission: improve access to essential medicines by offering high-quality treatments at affordable prices. Over time, Amneal has evolved from a generics-focused business into a more diversified pharmaceutical platform spanning affordable medicines, specialty pharmaceuticals and distribution services. ([investors.amneal.com](https://investors.amneal.com/news/press-releases/press-release-details/2026/Amneal-Unveils-Bold-New-Brand-to-Reimagine-Whats-Possible-in-Making-Medicine-Accessible-for-All-2026-PkNbhmgDo5/default.aspx?utm_source=openai)) Today, Amneal reports three business segments: Affordable Medicines, Specialty and AvKARE. Affordable Medicines includes retail generics, sterile injectables, biosimilars and certain international revenues. This segment covers a broad portfolio across dosage forms and delivery systems, including more complex products that face higher technical and regulatory barriers than commoditized generics. The Specialty segment is centered mainly on central nervous system and endocrine disorders. AvKARE provides pharmaceuticals, medical and surgical products and services, primarily to U.S. government agencies and institutional customers. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1723128/000172312825000012/R35.htm?utm_source=openai)) From a competitive standpoint, Amneal’s differentiation lies in its ability to participate across multiple parts of the pharmaceutical value chain. It competes in high-volume generics, but also in more technically demanding injectables, biosimilars and branded specialty therapies. The company also highlights a sizable U.S. manufacturing and R&D footprint, which supports supply-chain resilience, domestic production capabilities and regulatory execution. Recent company materials describe Amneal as one of the leading U.S.-based companies in the generics market by prescriptions, underscoring its scale in affordable medicines. ([amneal.com](https://amneal.com/making-medicines-more-accessible-right-here-in-america/?utm_source=openai)) Key products have become increasingly important to the investment case. CREXONT, an extended-release carbidopa/levodopa product for Parkinson’s disease, received FDA approval in 2024 and began commercialization the same year, strengthening Amneal’s Specialty franchise. In 2025, the company also secured FDA approval for Brekiya, described as the first and only ready-to-use dihydroergotamine autoinjector for adult migraine with or without aura and cluster headaches, and launched it commercially in October 2025. These launches point to a gradual mix shift toward more differentiated, higher-value products. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1723128/000172312824000032/amrx-20240630.htm?utm_source=openai)) Recent developments have been constructive. Amneal said all three segments posted double-digit revenue growth in 2024 in results released in early 2025; Brekiya was approved by the FDA in May 2025; the company announced a refinancing of its existing credit agreement in July 2025; it reported positive interim Phase 4 data for CREXONT in December 2025; and in January 2026 it unveiled a refreshed brand identity to reflect its transition into a diversified global biopharmaceutical leader. ([investors.amneal.com](https://investors.amneal.com/news/press-releases/press-release-details/2025/Amneal-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results/default.aspx?utm_source=openai))